Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

VYNE Therapeutics Inc. Common Stock (VYNE)

Pharmaceutical Preparations

https://www.vynetherapeutics.com

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

685 ROUTE 202/206 N., SUITE 301
BRIDGEWATER, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/25/2018

Market Cap

26,897,509

Shares Outstanding

13,960,000

Weighted SO

13,957,324

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

AKTX --.--%

SLRX --.--%

AXLA --.--%

MGTA --.--%

HSTO --.--%

FWBI --.--%

SABS --.--%

VCNX --.--%

GOVX --.--%

Beta

1.4560

Last Div

0.0000

Range

1.57-4.86

Chg

-0.0086

Avg Vol

53982

Mkt Cap

26897509

Exch

NASDAQ

Country

US

Phone

800 775 7936

DCF Diff

-0.7962

DCF

2.6642

Div Yield

0.0000

P/S

55.3447

EV Multiple

0.0847

P/FV

1.0531

Div Yield %

0.0000

P/E

-2.7754

PEG

-0.0375

Payout

0.0000

Current Ratio

7.1274

Quick Ratio

7.1274

Cash Ratio

2.5230

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

-63.4609

Pretax Margin

-57.3230

Net Margin

-58.4527

Eff Tax Rate

-0.0204

ROA

-0.3279

ROE

-0.4396

ROCE

-0.4118

NI/EBT

1.0197

EBT/EBIT

0.9033

EBIT/Rev

-63.4609

Debt Ratio

0.0017

D/E

0.0019

LT Debt/Cap

0.0003

Total Debt/Cap

0.0019

Int Coverage

-117.2700

CF/Debt

-184.4966

Equity Multi

1.1573

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

3.2185

Asset Turnover

0.0056

OCF/Share

-0.6282

FCF/Share

-0.6282

Cash/Share

1.8350

OCF/Sales

-55.0453

FCF/OCF

1.0000

CF Coverage

-184.4966

ST Coverage

-222.9333

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.0531

P/B

1.0531

P/S

55.3447

P/E

-2.7754

P/FCF

-1.0054

P/OCF

-2.9472

P/CF

-2.9472

PEG

-0.0375

P/S

55.3447

EV Multiple

0.0847

P/FV

1.0531

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 13, 07:45 VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Benzinga Oct 30, 13:29 Positive Momentum For VYNE Therapeutics' Psoriasis, Rheumatoid Arthritis Candidate - Analyst Expresses Encouragement Benzinga Oct 30, 13:29 Positive Momentum For VYNE Therapeutics' Psoriasis, Rheumatoid Arthritis Candidate - Analyst Expresses Encouragement GlobeNewswire Inc. Oct 30, 07:20 VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202 GlobeNewswire Inc. Oct 30, 07:05 VYNE Therapeutics Announces Private Placement of $88 Million

Revenue Product Segmentation